• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Oxford BioMedica plc (LSE: OXB)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk *

 

	Start	1996-01-01 splitoff predec
	Group	Oxford BioMedica (Group)
	Predecessor	Oxford BioMedica Ltd.
	Industry	gene therapy
	Person	Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
	Person 2	Paynter, Stuart (Oxford BioMedica 201708– CFO before De La Rue plc + Shire Pharmaceuticals + Steris)
	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Windrush Court Transport Way
	City	OX4 6LT Oxford
	Tel	+44-1865-783000
		Address record changed: 2018-07-24
Basic data	Employees	D: 101 to 500 (2018-12-31)
	Currency	GBP
	Annual sales	66,778,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	7,541,000 (2018-12-31)
	Cash	32,244,000 (2018-12-31)
		* Document for �About Section�: Oxford BioMedica plc. (3/7/16). "Press Release: Oxford BioMedica Announces Expanded Collaboration and Licence with Immune Design". Oxford.
		Record changed: 2019-06-09

Advertisement

More documents for Oxford BioMedica (Group)

• [1] Oxford BioMedica plc. (5/28/19). "Press Release: Oxford BioMedica Announces Strategic Investment by Novo Holdings A/S". Oxford....
• [2] Oxford BioMedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
• [3] Oxford BioMedica plc. (3/12/19). "Press Release: Oxford Biomedica Announces R&D Collaboration with Microsoft to Improve Gene and Cell Therapy Manufacturing Using the Intelligent Cloud and Machine Learning". Oxford....
• [4] Oxford BioMedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
• [5] Oxford BioMedica plc. (11/23/18). "Press Release: Oxford BioMedica Announces New Digital Framework Initiative to Streamline the Production of Next-generation Medicines with Cash Injection from Innovate UK". Oxford....
• [6] Oxford BioMedica plc. (6/6/18). "Press Release: Oxford BioMedica and Axovant Sciences Enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease". Oxford....
• [7] Oxford BioMedica plc. (2/15/18). "Press Release: Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy". Oxford....
• [8] Oxford BioMedica plc. (9/4/17). "Press Release: Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York". Oxford....
• [9] Oxford BioMedica plc. (8/17/17). "Press Release: Interim Results for the Six Months Ended 30 June 2017". Oxford....
• [10] Oxford BioMedica plc. (8/11/17). "Press Release: Oxford BioMedica Announces a £2 Million Two-year Collaboration Co-funded by Innovate UK". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.